Orbifloxacin (brand name Orbax) is a fluoroquinolone antibiotic which is approved for use in dogs, marketed by Schering-Plough Animal Health. It is a synthetic quinolone derivative that exerts bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, showing potent activity against a broad range of Gram negative and some Gram positive pathogens encountered in veterinary practice. Chemically it contains a substituted piperazinyl side chain that contributes to its spectrum and pharmacokinetic properties. Orbifloxacin is formulated for oral administration in tablets and as an oral suspension, displays good oral bioavailability in the canine species, and is used in clinical practice following susceptibility testing and label indications. Typical technical characterization includes assay by validated HPLC methods, identification by retention time and mass spectrometry, and stability profiling under ICH conditions to define shelf life and storage.
Parent: Orbifloxacin
Parent: Orbifloxacin
Parent: Orbifloxacin
Parent: Orbifloxacin
Parent: Orbifloxacin
Parent: Orbifloxacin
Impurities and related compounds are monitored as part of release and stability testing and are controlled in accordance with ICH impurity guidelines and routine pharmacopeial practice. Typical quality specifications used by manufacturers limit any single identified related compound to low subpercent levels and limit total organic impurities to about 1.0 percent or less; common control ranges are individually 0.1 to 0.5 percent for specified impurities and not more than 1.0 percent total. Related compounds that are routinely monitored include N desmethyl derivatives of the piperazinyl side chain, N oxide species, and degradation products arising from decarboxylation or ring modification; these specified impurities are typically assigned individual acceptance limits within the 0.1 to 0.5 percent range and unspecified impurities are controlled at lower reporting limits. Residual solvents, heavy metals, and water content are controlled against ICH Q3C and Q3D and pharmacopeial thresholds as part of the finished product specification.
Orbifloxacin is used to treat bacterial infections in dogs caused by susceptible organisms, commonly including skin and soft tissue infections, urinary tract infections, and certain respiratory infections; use should follow label indications, culture and sensitivity testing when possible, and veterinary guidance.
